Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
DGNeurologie
Erschienen in: DGNeurologie 3/2021

30.03.2021 | HIV | Leitlinie

S1-Leitlinie: Diagnostik und Therapie HIV-1-assoziierter neurologischer Erkrankungen

Leitlinie der Deutschen Gesellschaft für Neurologie

verfasst von: PD Dr. Katrin Hahn, Prof. Dr. Matthias Maschke

Erschienen in: DGNeurologie | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Auszug

Die UNAIDS startete 2014 die 90-90-90-Strategie, die besagt, dass in 2030 weltweit 90 % aller HIV-infizierten Menschen diagnostiziert, 90 % aller HIV-infizierten Menschen eine antiretrovirale Therapie erhalten und 90 % aller HIV-infizierten Menschen mit antiretroviraler Therapie virologisch supprimiert sein sollen. …
Literatur
1.
Omeragic A et al (2020) Potential pharmacological approaches for the treatment of HIV‑1 associated neurocognitive disorders. Fluids Barriers CNS 17(1):42PubMedPubMedCentralCrossRef
2.
3.
Eggers C et al (2017) HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol 264(8):1715–1727PubMedPubMedCentralCrossRef
4.
Eggers C et al (2003) Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17(13):1897–1906PubMedCrossRef
5.
Valcour VG et al (2007) Neuropsychological abnormalities in patients with dementia in CRF 01_AE HIV‑1 infection. Neurology 68(7):525–527PubMedCrossRef
6.
Wright EJ et al (2018) Global developments in HIV neurology. Handb Clin Neurol 152:265–287PubMedCrossRef
7.
8.
9.
Spudich S et al (2019) Potential for early antiretroviral therapy to reduce central nervous system HIV‑1 persistence. AIDS 33(Suppl 2):S135–S144PubMedCrossRef
10.
11.
Sturdevant CB et al (2015) Compartmentalized replication of R5 T cell-tropic HIV‑1 in the central nervous system early in the course of infection. PLoS Pathog 11(3):e1004720PubMedPubMedCentralCrossRef
12.
Sillman B et al (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21–40PubMedCrossRef
13.
Brew BJ, Barnes SL (2019) The impact of HIV central nervous system persistence on pathogenesis. AIDS 33(Suppl 2):S113–S121PubMedCrossRef
14.
Gelman BB, Endsley J, Kolson D (2018) When do models of NeuroAIDS faithfully imitate “the real thing”? J Neurovirology 24(2):146–155CrossRef
15.
Kahn JO, Walker BD (1998) Acute human immunodeficiency virus type 1 infection. N Engl J Med 339(1):33–39PubMedCrossRef
16.
17.
Salahuddin M et al (2020) Prevalence and predictors of neurocognitive impairment in Ethiopian population living with HIV. HIV AIDS 12:559–572
18.
Kranick SM, Nath A (2012) Neurologic complications of HIV‑1 infection and its treatment in the era of antiretroviral therapy. Continuum 18(6 Infectious Disease):1319–1337PubMedPubMedCentral
19.
Antinori A et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799PubMedCrossRef
20.
Ciccarelli N (2020) Considerations on nosology for HIV-associated neurocognitive disorders: it is time to update? Infection 48(1):37–42PubMedCrossRef
21.
22.
Grant I et al (2014) Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 82(23):2055–2062PubMedPubMedCentralCrossRef
23.
Brew BJ (2001) HIV neurology, 3. Aufl. Oxford University Press, New York
24.
25.
Smail RC, Brew BJ (2018) HIV-associated neurocognitive disorder. Handb Clin Neurol 152:75–97PubMedCrossRef
26.
Power C et al (1995) HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 8(3):273–278PubMedCrossRef
27.
Davis HF et al (2002) Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 12(1):29–31, 38PubMed
28.
Smith CA et al (2003) Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J Acquir Immune Defic Syndr 33(1):116–118PubMedCrossRef
29.
Skinner S et al (2009) Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med 10(4):246–252PubMedCrossRef
30.
Marin-Webb V et al (2016) Validation of the international HIV dementia scale as a screening tool for HIV-associated neurocognitive disorders in a German-speaking HIV outpatient clinic. PLoS ONE 11(12):e168225PubMedPubMedCentralCrossRef
31.
Simioni S et al (2009) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24(9):1243–1250CrossRef
32.
Sakamoto M et al (2013) Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr 62(1):36–42PubMedPubMedCentralCrossRef
33.
Kinai E et al (2017) Association of age and time of disease with HIV-associated neurocognitive disorders: a Japanese nationwide multicenter study. J Neurovirol 23(6):864–874PubMedCrossRef
34.
Valcour V et al (2004) Higher frequency of dementia in older HIV‑1 individuals: the Hawaii Aging with HIV‑1 Cohort. Neurology 63(5):822–827PubMedCrossRef
35.
Brew BJ (2016) Has HIV-associated neurocognitive disorders now transformed into vascular cognitive impairment? AIDS 30(15):2379–2380PubMedCrossRef
36.
Schuster RM, Gonzalez Substance Abuse R (2012) Hepatitis C, and aging in HIV: common cofactors that contribute to neurobehavioral disturbances. Neurobehav HIV Med 2012(4):15–34PubMedPubMedCentral
37.
Gonzalez R et al (2011) Impact of HIV and a history of marijuana dependence on procedural learning among individuals with a history of substance dependence. J Clin Exp Neuropsychol 33(7):735–752PubMedPubMedCentralCrossRef
38.
39.
Arendt G (2005) Neurologische Manifestationen der HIV-Infektion in der Ära der hochaktiven antiretroviralen Therapie (HAART). Fortschr Neurol Psychiatr 73:1–10CrossRef
40.
Petito CK et al (1986) Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 45(6):635–646PubMedCrossRef
41.
Hahn K (2020) Neuromuscular complications of HIV infection. Nervenheilkunde 39:533–535
42.
Geraci AP, Simpson DM (2001) Neurological manifestations of HIV‑1 infection in the HAART era. Compr Ther 27(3):232–241PubMedCrossRef
43.
Marra CM, Boutin P, Collier AC (1998) Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. Neurology 51(6):1678–1681PubMedCrossRef
44.
Morgello S et al (2004) HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 61(4):546–551PubMedCrossRef
45.
Ellis RJ et al (2010) Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 67(5):552–558PubMedPubMedCentralCrossRef
46.
47.
Hahn K et al (2008) Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons. Exp Neurol 210(1):30–40PubMedCrossRef
48.
Moyle GJ, Sadler M (1998) Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 19(6):481–494PubMedCrossRef
49.
50.
Prior DE, Song N, Cohen JA (2018) Neuromuscular diseases associated with Human Immunodeficiency Virus infection. J Neurol Sci 387:27–36PubMedCrossRef
51.
Ghrenassia E et al (2015) The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. J Autoimmun 59:19–25PubMedCrossRef
52.
Moulignier A et al (1997) Peripheral neuropathy in human immunodeficiency virus-infected patients with the diffuse infiltrative lymphocytosis syndrome. Ann Neurol 41(4):438–445PubMedCrossRef
53.
Arendt G (2000) Strategien aus Sicht des Neurologen. Ärzteblatt 97(15):A-972–A973
54.
Casademont J et al (1996) The effect of zidovudine on skeletal muscle mtDNA in HIV‑1 infected patients with mild or no muscle dysfunction. Brain 119(Pt 4):1357–1364PubMedCrossRef
55.
Authier FJ, Chariot P, Gherardi RK (2005) Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 32(3):247–260PubMedCrossRef
56.
Hiniker A, Daniels BH, Margeta M (2016) T‑cell-mediated inflammatory Myopathies in HIV-positive individuals: a histologic study of 19 cases. J Neuropathol Exp Neurol 75(3):239–245PubMedPubMedCentralCrossRef
57.
58.
Uruha A et al (2016) Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology 86(3):211–217PubMedCrossRef
59.
Silva AMS et al (2017) Clinical, histological and radiological responses to methylprednisolone in HIV-associated rod myopathy. Neuromuscul Disord 27(8):756–759PubMedCrossRef
60.
UK Collaborative HIV Cohort (CHIC) Study Steering Committee et al (2011) HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 18(3):527–534CrossRef
61.
Tan IL et al (2012) HIV-associated opportunistic infections of the CNS. Lancet Neurol 11(7):605–617PubMedCrossRef
62.
Albarillo F, O’Keefe P (2016) Opportunistic neurologic infections in patients with acquired immunodeficiency syndrome (AIDS). Curr Neurol Neurosci Rep 16(1):10PubMedCrossRef
63.
Maschke M (2020) Opportunistic infections in patients with HIV. Nervenheilkunde 39:536–541
64.
Brandsma D, Bromberg JEC (2018) Primary CNS lymphoma in HIV infection. Handb Clin Neurol 152:177–186PubMedCrossRef
65.
Arendt G, Maschke M (2018) HIV-Infektionen und AIDS: neurologische Manifestationen. In: Diener HC, Gerloff C, Dieterich M (Hrsg) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, S 655–683
66.
Bowen L, Nath A, Smith B (2018) CNS immune reconstitution inflammatory syndrome. Handb Clin Neurol 152:167–176PubMedCrossRef
67.
Shelburne SA et al (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19(4):399–406PubMedCrossRef
68.
69.
Arendt G et al (1992) Improvement of motor performance of HIV-positive patients under AZT therapy. Neurology 42(4):891–896PubMedCrossRef
70.
Cysique LA, Maruff P, Brew BJ (2006) The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis. J Int Neuropsychol Soc 12(3):368–382PubMedCrossRef
71.
Heaton RK et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17(1):3–16PubMedCrossRef
72.
73.
Su T et al (2017) Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy. AIDS 31(6):847–856PubMedCrossRef
74.
Young AC et al (2014) Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology 83(18):1592–1600PubMedPubMedCentralCrossRef
75.
Fernandez-Cruz AL, Fellows LK (2017) The electrophysiology of neuroHIV: A systematic review of EEG and MEG studies in people with HIV infection since the advent of highly-active antiretroviral therapy. Clin Neurophysiol 128(6):965–976PubMedCrossRef
76.
Schmidbauer M et al (1992) Morphological spectrum, distribution and clinical correlation of white matter lesions in AIDS brains. Neuropathol Appl Neurobiol 18(5):489–501PubMedCrossRef
77.
Moodley K, Bill PL, Patel VB (2017) A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients. Neurol Neuroimmunol Neuroinflamm 4(2):e315PubMedCrossRef
78.
Mochan A, Anderson D, Modi G (2016) CIDP in a HIV endemic population: A prospective case series from Johannesburg, South Africa. J Neurol Sci 363:39–42PubMedCrossRef
79.
Evers S et al (2004) Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance. Aids Res Hum Retroviruses 20(5):483–491PubMedCrossRef
80.
Letendre S et al (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1):65–70PubMedPubMedCentralCrossRef
81.
Handoko R, Spudich S (2019) Treatment of central nervous system manifestations of HIV in the current era. Semin Neurol 39(3):391–398PubMedCrossRef
82.
83.
Eggers C, Hoetelmans R, Laer S (2020) Zidovudine and lamivudine reach higher concentrations in ventricular than in lumbar human cerebrospinal fluid. AIDS 34(13):1883–1889PubMedCrossRef
84.
85.
Fabbiani M et al (2015) Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility. Antivir Ther 20(4):441–447PubMedCrossRef
86.
Kanmogne GD et al (2012) Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. IJN 7:2373–2388PubMedCrossRefPubMedCentral
87.
Epstein AA et al (2013) Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. J Neuroimmune Pharmacol 8(5):1224–1238PubMedPubMedCentralCrossRef
88.
89.
90.
Thakur KT et al (2019) Global HIV neurology: a comprehensive review. AIDS 33(2):163–184PubMedCrossRef
91.
Dalakas MC, Semino-Mora C, Leon-Monzon M (2001) Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 81(11):1537–1544PubMedCrossRef
92.
Estanislao L, Thomas D, Simpson D (2004) HIV neuromuscular disease and mitochondrial function. Mitochondrion 4(2–3):131–139PubMedCrossRef
93.
Kallianpur AR, Hulgan T (2009) Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics 10(4):623–637PubMedCrossRef
94.
95.
Chow FC et al (2017) Relationship between HIV infection, antiretroviral therapy, inflammatory markers, and cerebrovascular endothelial function among adults in Urban China. J Acquir Immune Defic Syndr 74(3):339–346PubMedPubMedCentralCrossRef
96.
Boly L, Cafaro V, Dyner T (2006) Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immune Defic Syndr 42(4):514–515PubMedCrossRef
97.
Bertrand L, Dygert L, Toborek M (2016) Antiretroviral treatment with efavirenz disrupts the blood-brain barrier integrity and increases stroke severity. Sci Rep 6:39738PubMedPubMedCentralCrossRef
98.
Decloedt EH, Maartens G (2013) Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf 12(6):841–846PubMedCrossRef
99.
100.
Markowitz M et al (1995) A preliminary study of ritonavir, an inhibitor of HIV‑1 protease, to treat HIV‑1 infection. N Engl J Med 333(23):1534–1539PubMedCrossRef
101.
Madeddu G et al (2012) Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS 26(18):2412–2415PubMedCrossRef
102.
Raffi F et al (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV‑1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING‑2 study. Lancet 381(9868):735–743PubMedCrossRef
103.
Govender R et al (2011) Neurologic and neurobehavioral sequelae in children with human immunodeficiency virus (HIV-1) infection. J Child Neurol 26(11):1355–1364PubMedCrossRef
104.
Okulicz JF et al (2011) Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther 8:18PubMedPubMedCentralCrossRef
105.
Okulicz JF et al (2013) The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Res 103(2–3):245–253PubMedCrossRef
106.
Birbeck GL et al (2012) Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS: report of the quality standards subcommittee of the American Academy of Neurology and the Ad hoc task force of the commission on therapeutic strategies of the international league against epilepsy. Neurology 78(2):139–145PubMedPubMedCentralCrossRef
107.
Centner CM et al (2018) Evolution of sensory neuropathy after initiation of antiretroviral therapy. Muscle Nerve 57(3):371–379PubMedCrossRef
108.
Sommer C et al (2018) Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden. S2e-Leitlinie. Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.​dgn.​org/​leitlinien. Zugegriffen: 14.12.2020
109.
Basu D et al (2006) Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arthritis Rheum Care Res 55(3):466–472CrossRef
110.
Phillips TJ et al (2010) Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE 5(12):e14433PubMedPubMedCentralCrossRef
111.
Simpson DM, Brown S, Tobias J (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70(24):2305–2313PubMedCrossRef
112.
Hahn K et al (2004) A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 251(10):1260–1266PubMedCrossRef
113.
Simpson DM et al (2010) Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74(5):413–420PubMedPubMedCentralCrossRef
114.
Simpson DM et al (2014) A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain 155(10):1943–1954PubMedCrossRef
115.
Kieburtz K et al (1998) A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 51(6):1682–1688PubMedCrossRef
116.
Shlay JC et al (1998) Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 280(18):1590–1595PubMedCrossRef
117.
Dinat N et al (2015) Randomized, double-blind, crossover trial of amitriptyline for analgesia in painful HIV-associated sensory neuropathy. PLoS ONE 10(5):e126297PubMedPubMedCentralCrossRef
118.
Thoden J et al (2013) Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/OAG) (AWMF 055/066). Infection 41(Suppl 2):91–115PubMedCentralCrossRef
119.
Dannemann B et al (1992) Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 116(1):33–43PubMedCrossRef
120.
Leport C et al (1988) Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med 84(1):94–100PubMedCrossRef
121.
Katlama C et al (1996) Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 22(2):268–275PubMedCrossRef
122.
Cortese I et al (2019) Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med 380(17):1597–1605PubMedCrossRef
123.
124.
Schofer H et al (2020of) Diagnosis and treatment of syphilis: Update of the S2k guidelines 2020 of the German STI Society (DSTIG) in cooperation with the following specialist societies: DAIG, dagna, DDG, DGA, DGGG, DGHM, DGI, DGN, DGPI, DGU, RKI. Hautarzt 71(12):969–999. https://​doi.​org/​10.​1007/​s00105-020-04672-6
125.
Ghanem KG et al (2009) Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 48(6):816–821PubMedCrossRef
Metadaten
Titel
S1-Leitlinie: Diagnostik und Therapie HIV-1-assoziierter neurologischer Erkrankungen
Leitlinie der Deutschen Gesellschaft für Neurologie
verfasst von
PD Dr. Katrin Hahn
Prof. Dr. Matthias Maschke
Publikationsdatum
30.03.2021
Verlag
Springer Medizin
Erschienen in
DGNeurologie / Ausgabe 3/2021
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI
https://doi.org/10.1007/s42451-021-00335-5

Weitere Artikel der Ausgabe 3/2021

DGNeurologie 3/2021 Zur Ausgabe

Editorial

Datenlage zu COVID-19: Vorsicht vor kausalen Verknüpfungen

Eine Frage des Rechts

Mehr Geld für Gutachten – zur Reform der Vergütung für Sachverständige

Neuro-Quiz

Meningoenzephalitis und ophthalmologische Symptome

CME Zertifizierte Fortbildung

CME: Morbus Fabry in der Neurologie

Erratum

Erratum zu: 69-jährige Frau mit progredienter Gangstörung

Leserbriefe

CK-Serumaktivität und Epilepsie

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein
Bildnachweise